Advertisement

Tumor Biology

, Volume 37, Issue 1, pp 1237–1244 | Cite as

MDR1 polymorphisms have an impact on the prognosis of Chinese diffuse large B cell lymphoma patients

  • Ying Ni
  • Guangli Yin
  • Zhengrui Xiao
  • Lei Fan
  • Li Wang
  • Yujie Wu
  • Hanxin Wu
  • Sixuan Qian
  • Wei Xu
  • Jianyong Li
  • Kourong Miao
  • Hairong Qiu
Original Article

Abstract

MDR1 (multidrug resistance 1) encodes an adenosine triphosphate (ATP)-dependent efflux transporter that plays a fundamental role in transportation of harmful compounds outside cells to maintain optimal health. The present study was aimed to investigate whether the MDR1 gene single nucleotide polymorphisms (SNPs) were associated with the prognosis of diffuse large B cell lymphoma (DLBCL). Three common SNPs, including C1236T, G2677T/A, and C3435T were focused on, and a total of 150 DLBCL patients from Jiangsu Han population were successively genotyped by polymerase chain reaction–allele-specific primers (PCR-ASP) method or DNA direct sequencing. At locus C1236T, patients carrying T allele (genotype CT and TT) had a prolonged overall survival (OS) when compared with patients with CC genotype (2-year OS 82.6 vs. 60.0 %, respectively; hazard ratio (HR) = 0.1, 95 % confidence interval (CI) 0.01–0.6, p = 0.016). At locus C3435T, complete remission/ complete remission unconfirmed (CR/CRu) rate in C allele group was significantly higher than T allele group (66.7 vs. 51.9 %, respectively; p = 0.009). The progression-free survival (PFS) curves of with T (genotype CT and TT) and without T (genotype CC) were significantly different (2-year PFS 46.4 % in with T group vs. 73.7 % in without T group, respectively; HR = 1.9, 95 % CI 1.0–3.6, p = 0.045). At locus G2677T/A, the age for genotypes AG and AT groups was significantly younger than the other genotypes (51.1 ± 12.6 vs. 57.7 ± 13.4 years, respectively; p = 0.033). In the haplotype analysis of loci 1236-3435, compared with T-C group, the C-T group displayed an inferior PFS rate (2-year PFS 23.0 vs. 50.6 %, respectively; HR = 7.8, 95 % CI 1.9–32.6, p = 0.005), while C-C and T-T groups showed an intermediate PFS rate. Our findings demonstrate that genotype CT + TT at locus C1236T, allele C, and genotype CC at locus C3435T might contribute to a relatively superior prognosis in DLBCL, as well as haplotype of T-C in loci 1236-3435. Besides, genotypes at locus G2677T/A might affect age at diagnosis, which has important prognostic value for DLBCL.

Keywords

Diffuse large B cell lymphoma (DLBCL) Multidrug resistance 1 (MDR1Polymorphism Prognosis 

Notes

Acknowledgments

This study was supported by grants from National Natural Science Foundation of China (81470329), National Public Health Grand Research Foundation (No. 201202017), Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institute (No. JX10231801), Program for Development of Innovative Research Teams in the First Affiliated Hospital of Nanjing Medical University, Project of National Key Clinical Specialty, National Science & Technology Pillar Program (No. 2014BAI09B12), and Project Funded by Jiangsu Provincial Special Program of Medical Science (No. BL2014086).

Conflicts of interest

None

References

  1. 1.
    Turner JJ, Morton LM, Linet MS, Clarke CA, Kadin ME, Vajdic CM, et al. InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO Classification (2008): update and future directions. Blood. 2010;116(20):e90–8.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Xu W, Fan L, Miao Y, Xu H, Yu L, Xu X, et al. Distribution of lymphomas subtypes in Jiangsu Province: a multicenter analysis of 5147 cases. ZhonghuaXue Ye Xue Za Zhi. 2014;35(4):300–3.Google Scholar
  3. 3.
    Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell. J Clin Oncol. 2006;24(19):3121–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomized study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12(11):1013–22.CrossRefPubMedGoogle Scholar
  5. 5.
    Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23(22):5027–33.CrossRefPubMedGoogle Scholar
  6. 6.
    Bodor M, Kelly EJ, Ho RJ. Characterization of the human MDR1 gene. AAPS J. 2005;7(1):E1–5.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Kasuya K, Tsuchida A, Suzuki M, Nagakawa Y, Tanaka H, Ota H, et al. Single nucleotide polymorphism of multidrug-resistance 1 and anti- multidrug-resistance 1 single chain antibody treatment for the pancreatic cancer cell line. Hepatogastroenterology. 2011;59(113):272–5.Google Scholar
  8. 8.
    Pongstaporn W, Pakakasama S, Chaksangchaichote P, Pongtheerat T, Hongeng S, Permitr S. MDR1 C3435T and C1236T polymorphisms: association with high-risk childhood acute lymphoblastic leukemia. Asian Pac J Cancer Prev. 2015;16(7):2839–43.CrossRefPubMedGoogle Scholar
  9. 9.
    Gutierrez-Rubio SA, Quintero-Ramos A, Duran-Cardenas A, Franco-Topete RA, Castro-Cervantes JM, Oceguera-Villanueva A, et al. 1236 C/T and 3435 C/T polymorphisms of the ABCB1 gene in Mexican breast cancer patients. Genet Mol Res. 2015;14(1):1250–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Yaya K, Hind D, Meryem Q, Asma Q, Said B, Sellama N. Single nucleotide polymorphisms of multidrug resistance gene 1 (MDR1) and risk of chronic myeloid leukemia. Tumour Biol. 2014;35(11):10969–75.CrossRefPubMedGoogle Scholar
  11. 11.
    Qiu H, Dong H, Pan S, Miao K. The single nucleotide polymorphism and haplotype analysis of MDR1 in Jiangsu Han population of China. Biomed Pharmacother. 2012;66(6):459–63.CrossRefPubMedGoogle Scholar
  12. 12.
    Ma L, Liu H, Ruan L, Yang X, Yang H, Feng Y. Multidrug resistance gene 1 C1236T polymorphism and susceptibility to leukemia: a meta-analysis. Biomed Rep. 2015;3(1):83–7.PubMedGoogle Scholar
  13. 13.
    Vine J, Cohen SB, Ruchlemer R, Goldschmidt N, Levin M, Libster D, et al. Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia. Leuk Lymphoma. 2014;55(11):2525–31.CrossRefPubMedGoogle Scholar
  14. 14.
    Hu LL, Yu B, Yang J. MDR1 polymorphisms associated with risk and survival in diffuse large B-cell lymphoma. Leuk Lymphoma. 2013;54(6):1188–93.CrossRefPubMedGoogle Scholar
  15. 15.
    Mhaidat NM, Alshogran OY, Khabour OF, Alzoubi KH, Matalka II, Haddadin WJ, et al. Multi-drug resistance 1 genetic polymorphism and prediction of chemotherapy response in Hodgkin’s lymphoma. J Exp Clin Cancer Res. 2011;30:68.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of tumors of haematopoietic and lymphoid tissues. Lyon: WHO; 2008.Google Scholar
  17. 17.
    Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, et al. Non-Hodgkin’s lymphomas, version 4.2014. J Nat Compr Cancer Netw. 2014;12(9):1282–303.Google Scholar
  18. 18.
    Excoffier L, Laval G, Schneider S. Arlequin (version 3.0): an integrated software package for population genetics data analysis. Evol Bioinformatics Online. 2007;1:47–50.Google Scholar
  19. 19.
    Brambila-Tapia AJ. MDR1 (ABCB1) polymorphisms: functional effects and clinical implications. Rev Investig Clin. 2013;65(5):445–54.Google Scholar
  20. 20.
    Johnatty SE, Beesley J, Gao B, Chen X, Lu Y, Law MH, et al. ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecol Oncol. 2013;131(1):8–14.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Rao DN, Anuradha C, Vishnupriya S, Sailaja K, Surekha D, Raghunadharao D, et al. Association of an MDR1 gene (C3435T) polymorphism with acute leukemia in India. Asian Pac J Cancer Prev. 2010;11(4):1063–6.PubMedGoogle Scholar
  22. 22.
    Chen B, Zhang W, Fang J, Jin Z, Li J, Yu Z, et al. Influence of the MDR1 haplotype and CYP3A5 genotypes on cyclosporine blood level in Chinese renal transplant recipients. Xenobiotica. 2009;39(12):931–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Bellusci CP, Rocco C, Aulicino P, Mecikovsky D, Curras V, Hegoburu S, et al. Influence of MDR1 C1236T polymorphism on lopinavir plasma concentration and virological response in HIV-1-infected children. Gene. 2013;522(1):96–101.CrossRefPubMedGoogle Scholar
  24. 24.
    Deenik W, van der Holt B, Janssen JJ, Chu IW, Valk PJ, Ossenkoppele GJ, et al. Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib. Blood. 2010;116(26):6144–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Ray A, Tennakoon L, Keller J, Sarginson JE, Ryan HS, Murphy GM, et al. MDR1 (ABCB1) predicts remission on P-gp substrates in chronic depression. Pharmacogenomics J. 2014. doi: 10.1038/tpj.2014.72.PubMedGoogle Scholar
  26. 26.
    Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS, et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics. 2002;12(6):437–50.CrossRefPubMedGoogle Scholar
  27. 27.
    Frittitta L, Ercolino T, Bozzali M, Argiolas A, Graci S, Santagati MG, et al. A cluster of three single nucleotide polymorphismsin the 3′-untranslated region of human glycoprotein PC-1 gene stabilizes PC-1 mRNA and is associated with increased PC-1 protein content and insulin resistance-related abnormalities. Diabetes. 2001;50(8):1952–5.CrossRefPubMedGoogle Scholar
  28. 28.
    Vinolas N, Provencio M, Reguart N, Cardenal F, Alberola V, Sanchez-Torres JM, et al. Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer. 2011;71(2):191–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Perloff MD, von Moltke LL, Störmer E, Shader RI, Greenblatt DJ. Saint John’s wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol. 2001;134(8):1601–8.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Suthandiram S, Gan G-G, Zain SM, Bee P-C, Lian L-H, Chang K-M, et al. Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies. Pharmacogenomics. 2014;15(11):1479–94.CrossRefPubMedGoogle Scholar
  31. 31.
    Xuan M, Li H, Fu R, Yang Y, Zhang D, Zhang X, et al. Association of ABCB1 gene polymorphisms and haplotypes with therapeutic efficacy of glucocorticoids in Chinese patients with immune thrombocytopenia. Hum Immunol. 2014;75(4):317–21.CrossRefPubMedGoogle Scholar
  32. 32.
    Green H, Falk IJ, Lotfi K, Paul E, Hermansson M, Rosenquist R, et al. Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype. Pharmacogenomics J. 2012;12(2):111–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Loscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia. 2009;50(1):1–23.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Ying Ni
    • 1
    • 2
  • Guangli Yin
    • 1
    • 2
  • Zhengrui Xiao
    • 1
    • 2
  • Lei Fan
    • 1
    • 2
  • Li Wang
    • 1
    • 2
  • Yujie Wu
    • 1
    • 2
  • Hanxin Wu
    • 1
    • 2
  • Sixuan Qian
    • 1
    • 2
  • Wei Xu
    • 1
    • 2
  • Jianyong Li
    • 1
    • 2
  • Kourong Miao
    • 1
    • 2
  • Hairong Qiu
    • 1
    • 2
  1. 1.Department of Hematology, The First Affiliated Hospital of Nanjing Medical UniversityJiangsu Province HospitalNanjingChina
  2. 2.Collaborative Innovation Center for Cancer Personalized MedicineNanjing Medical UniversityNanjingChina

Personalised recommendations